Mitigating the Risk of Pitfalls in Nasal Drug Product Development, Testing and Manufacturing
Summary: Over the past five years, the increased approval rate of intranasally delivered molecules has provided evidence of growing interest and opportunities in the route for both local and systemic administration. However, there are as many risks to developing and manufacturing nasal spray drug products as there are opportunities, especially in the area of chemistry, manufacturing and controls (CMC). Failing to identify and mitigate such risks can lead to noncompliance with performance and quality requirements, bringing safety and efficacy issues that could jeopardize patients as well as the entire drug development program.
In this webinar, experts discuss problems common to the development, testing and manufacturing of intranasal drug products, their potential causes, and possible consequences. Experts then make recommendations for preventing them, or mitigating their effects.